Jun 20 |
Bausch files patent suit against Norwich over generic Xifaxan
|
Jun 20 |
Bausch Health Brings Patent Infringement Lawsuit Against Norwich Pharmaceuticals
|
Jun 16 |
With 63% ownership of the shares, Bausch Health Companies Inc. (NYSE:BHC) is heavily dominated by institutional owners
|
Jun 14 |
Bausch Health Reports Promising R&D Trial Updates on Amiselimod and Scientific Data Presented at International Healthcare Conferences
|
May 29 |
Bausch + Lomb’s enVista Envy IOL obtains Health Canada approval
|
May 23 |
Bausch Health, Canada Inc. Announces Additional Public Drug Plan Listings for PrUCERIS(R) (Budesonide) Aerosol Foam To Treat Mild to Moderate Distal Ulcerative Colitis in Adults
|
May 17 |
Salix to Present Late-Breaking Data from Phase 2 Trial of Amiselimod in Active Ulcerative Colitis at Digestive Disease Week 2024
|
May 15 |
RBC Notes Updates on Bausch Xifaxan Patent Litigation with Norwich
|
May 15 |
Bausch Health Announces 2024 Annual Meeting of Shareholder Results
|
May 14 |
Bausch issues update on Xifaxan patent dispute with Norwich
|